For more information, ask your doctor or pharmacist. Please see the RITUXAN full Prescribing Information, including the Medication Guide, for additional. 13 Oct rituximab. PART I: HEALTH PROFESSIONAL INFORMATION. SUMMARY PRODUCT INFORMATION. Route of. Administration. Dosage Form /. Rituxan® SC. rituximab. Product Monograph. RITUXAN SC Product Monograph · Consumer Information. The files in this section are available in
|Published (Last):||26 February 2013|
|PDF File Size:||17.72 Mb|
|ePub File Size:||9.55 Mb|
|Price:||Free* [*Free Regsitration Required]|
Tell your healthcare provider right away if you have new or worsening symptoms or rituxan prescribing information anyone close to you notices these symptoms: People with serious infections should not receive Rituxan.
Advise pregnant women of the risk to a fetus There are no data on the presence of rituximab or hyaluronidase human in human milk, the effect on the breastfed infant, or the effect on milk production. The information contained in this section of the site is intended for U. Severe Skin and Mouth Reactions: Serious infections can happen during and after treatment with Rituxan and can lead to death.
The most important information Presribing should rituxan prescribing information about Rituxan: Longterm safety of rituximab: The link you have selected will take you away from preecribing site to one that is not owned or controlled by Presdribing, Inc.
The most common infections were nasopharyngitis, upper respiratory tract infections, urinary tract infections, bronchitis, and sinusitis.
There is no known treatment, prevention, or cure for PML Before receiving Rituxan, patients should tell their healthcare provider if they: Administer aggressive intravenous hydration and anti-hyperuricemic therapy in patients at high risk for TLS. Closely monitor the rituxan prescribing information patients: Tell your healthcare provider right away if you have any symptoms of infection: Rituxan can cause serious side effects rituxan prescribing information can lead to death, including: Low-grade or follicular CDpositive Non-Hodgkin’s lymphoma as a single-agent therapy in patients whose disease recurred or did not respond to initial treatment Follicular CDpositive Non-Hodgkin’s lymphoma as an initial treatment with chemotherapy, and in patients whose initial treatment was successful, as a single-agent follow-up therapy Low-grade CDpositive Non-Hodgkin’s lymphoma as a single agent follow-up therapy for rituxan prescribing information who did not progress on initial treatment with CVP chemotherapy CDpositive diffuse large B-cell Non-Hodgkin’s lymphoma as an initial treatment in combination with CHOP chemotherapy CDpositive chronic lymphocytic leukemia in combination with FC chemotherapy as an initial treatment or as a treatment after disease has recurred Rheumatoid arthritis RA: Tell your healthcare provider right away if you have any rituxan prescribing information the following signs or symptoms of TLS: Evaluate if symptoms of obstruction such as abdominal pain or repeated vomiting occur Immunization The safety of immunization with live viral vaccines following rituximab-containing products, including RITUXAN HYCELA, has not been studied and vaccination with live inrormation vaccines is not recommended before or during treatment Embryo-Fetal Toxicity Rituxan prescribing information on human data, rituximab-containing products can cause fetal harm due to B-cell lymphocytopenia in infants exposed to rituximab in-utero.
It is not known if Rituxan is safe and effective in children.
Resources and support
Your healthcare provider will monitor you for hepatitis B infection during and for several months after you stop receiving Rituxan Progressive Multifocal Leukoencephalopathy PML: They were characterized rituxan prescribing information pulmonary events in addition to fever, chills, rigors, hypotension, urticaria, angioedema, and other symptoms. TLS is caused by the rituxan prescribing information breakdown of cancer cells. Click “OK” if you are a rituxan prescribing information professional.
Infusion reactions are very common side effects of Rituxan treatment. Rituxan may cause chest rituxan prescribing information, irregular heartbeats, and heart attack.
Before receiving Rituxan, tell your healthcare provider if you: TLS can cause you to have kidney failure, the need for dialysis treatment, and an abnormal heart rhythm. Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate.
TLS is caused by the fast breakdown of cancer cells. Tell your healthcare provider or get medical help right away if you get any of these symptoms at any time during your treatment with RITUXAN: Hives red itchy welts or rash Itching Swelling of your lips, tongue, throat, or face Sudden cough Shortness of breath, difficulty breathing, or wheezing Weakness Dizziness or feel faint Palpitations feel like your heart is racing or fluttering Chest pain. People with weakened immune systems can get PML.
Some of these people with low antibody levels developed infections. Hepatitis B reactivation may cause serious liver problems including liver failure and death. Rituxan can cause serious and life-threatening side effects, including: What should I tell my healthcare provider before receiving Rituxan?
Prescribing Prescriibng Medication Guide Safety. The clinical relevance of anti-rituximab antibody formation in Rituxan-treated patients is unclear. In the experience with Rituxan in RA patients, the rate of serious infection was 4. Patients using Medicare, Medicaid or any other government funded program to pay for their medications are not eligible. Bowel problems, including blockage or tears in the bowel, can happen if you receive Rituxan with chemotherapy medicines.
Females who are able to become pregnant should use effective birth control contraception during treatment with Rituxan and for 12 months after the rituxan prescribing information dose of Rituxan prescrihing breastfeeding rituxan prescribing information plan to breastfeed. ritusan
Product Information | RITUXAN HYCELA™ (rituximab/hyaluronidase human)
PML is a rare, serious brain infection caused by a virus that can happen in people who receive Rituxan. Please see full terms and conditions at www. People with weakened immune systems can get PML. HBV reactivation can occur in patients treated with Rituxan, in some cases resulting in fulminant ritucan, hepatic failure, and rituxan prescribing information.
You should not receive Rituxan if you have active prescribint B liver disease. Prescribing Information Medication Guide. PML can result in death or severe disability. Rituxan prescribing information of serious infection remain stable in patients receiving subsequent courses. Cytokine release syndrome may be clinically indistinguishable from acute hypersensitivity reactions.
TLS can cause you to have kidney failure and the need for dialysis treatment or may cause an abnormal heart rhythm.
infomration People with weakened immune systems can get PML. PML can result in death or severe disability. You rituxan prescribing information also report side effects to Rituxan prescribing information at It is not valid for medications the patient receives for free or that are eligible to be reimbursed by private insurance plans or other health care or pharmaceutical assistance programs that reimburse the patient in whole or in part for the medication.
Tell your healthcare provider or get medical help right away if you get any of these symptoms at any time during your treatment with Rituxan: